Embedded PMO Advantage Radyus functions as an embedded extension of client R&D teams with a single PMO across regulatory, CMC, nonclinical and clinical workstreams, enabling capital efficiency by reducing vendor fragmentation and delivering investor-ready milestones.

End-to-End Program Management They offer end-to-end drug development coverage from preclinical candidate selection through Phase 2, including IND-enabling studies, regulatory strategy, CMC planning, and CRO/CDMO oversight—a compelling proposition for biotech firms seeking faster, compliant execution under one accountable partner.

Therapeutic Expertise Breadth With deep therapeutic expertise across immunology, oncology, infectious diseases, metabolic diseases, and neuroscience across multiple modalities, Radyus can support diversified portfolios and cross-program value creation.

Growth Credibility The appointment of Anna Walz to the Board of Directors to support growth with mid-size and large pharma clients signals credibility and readiness to engage larger partnerships, a favorable entry point for new enterprise-level deals.

Market Fit and Scale Serving global biotech and investment groups with a lean, scalable embedded R&D engine positions Radyus to win pilot projects and multi-program deals that align with investor timelines and regulatory expectations.